On 22 June 2026 China approved 恺力美 (satricabtagene autoleucel, satri-cel; development code CT041) for advanced gastric or gastro-oesophageal junction adenocarcinoma that is Claudin18.2-positive and HER2-negative, after at least two lines of treatment have failed. It is the first CAR-T product anywhere in the world approved for a solid tumour. Three days later, the oncology team led by Professor Liu Tianshu at Zhongshan Hospital, Fudan University, collected the T cells of the first commercial solid-tumor CAR-T patient in the world. Public follow-up reports say the patient has now completed the infusion, that imaging shows the tumour lesions shrinking, and that his general condition is good; long-term disease control is still being followed.
The two events sit three days apart, but they close a gap that took far longer than three days to build. At one end lies a decade of clinical research and a regulatory review; at the other, a patient receiving treatment under ordinary clinical care rather than inside a trial protocol.
That is what makes the moment awkward as well as encouraging. The question is no longer whether CAR-T can be made to work in a solid tumour. It is how to choose the right patient, how to run the whole pathway without gaps, and how to make the response last longer than a few months.
The short version
Approved: 恺力美 (satri-cel, CT041) targeting Claudin18.2, for Claudin18.2-positive and HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma after at least two prior lines. Nothing beyond that label is approved.
Pivotal evidence: CT041-ST-01, 156 patients, the first randomised controlled trial of a solid-tumor CAR-T anywhere in the world. Median progression-free survival of 3.25 months versus 1.77 months.
Safety: cytokine release syndrome in 95 percent of treated patients, almost all grade 1 to 2; no immune effector cell-associated neurotoxicity reported in the trial.
Naming: 恺力美 is the brand name, satricabtagene autoleucel the international non-proprietary name, satri-cel the short form and CT041 the development code. All four refer to the same product.
What CAR-T Actually Is
T cells are the immune system's mobile infantry. CAR-T treatment starts by collecting a patient's own T cells and engineering them to carry a chimeric antigen receptor, a synthetic receptor that acts as a guidance system, telling the cell which surface marker to look for. The modified cells are expanded outside the body, tested for identity, purity and potency, and then infused back. Inside the patient they keep hunting cells that display the matching target.
It is worth being blunt about what this is not. It is not an off-the-shelf anticancer injection. It is an individualised manufacturing and care pathway: eligibility assessment, apheresis, cell manufacture, sometimes bridging treatment while the product is being made, lymphodepleting chemotherapy, infusion, toxicity monitoring and long-term follow-up. Every one of those steps can fail, and each has to be staffed and scheduled.
Read the full sequence of steps in our guide to how CAR-T works.
Why Solid Tumors Are a Harder Problem
CAR-T has produced durable remissions in some leukaemias, lymphomas and multiple myeloma. Solid tumours are a different battlefield, and the difficulties compress into three barriers.
Barrier one: the target is not clean
Blood cancers often present a target that is uniform and well defined. Solid tumours are heterogeneous. The primary tumour and a metastatic deposit in the same patient can differ in target expression, and so can two regions of the same mass. A CAR-T that clears only the target-positive cells leaves the low-expressers and the negatives behind, and those are exactly the cells that grow back. The reverse problem is just as serious: several solid-tumor targets are also expressed at low level in normal tissue, which is where on-target, off-tumour toxicity comes from.
Barrier two: the tumour is hard to enter
Solid tumours build a physical wall: abnormal vasculature, dense stroma, and a scaffold of cancer-associated fibroblasts. A CAR-T population can expand impressively in the bloodstream and still never reach the core of the tumour.
Barrier three: the cells tire
Once inside, the cells meet hypoxia, competition for nutrients, an acidic metabolic environment, immunosuppressive cells and inhibitory signalling. Sustained fighting drives T-cell exhaustion, which erodes expansion, killing capacity and persistence.
So the real advance in solid tumors is not simply making T cells kill harder. It is solving recognition, infiltration and persistence at the same time, in the same product, in the same patient.
Why Claudin18.2
Claudin 18.2 is one isoform of the tight-junction protein claudin 18. In healthy tissue it sits inside the tight-junction structure of the gastric mucosa, largely hidden from immune cells. When gastric cancer develops, that architecture breaks down, and Claudin18.2 becomes exposed on the surface of a proportion of tumour cells. That combination, exposed on tumour and buried in normal tissue, is why antibodies, antibody-drug conjugates and cell therapies have all converged on it.
The approval does not mean CAR-T now works for solid tumours in general. It means the therapy has crossed the threshold from clinical research to commercial availability in one narrow, biomarker-selected group of patients with advanced gastric and gastro-oesophageal junction cancer.
See which solid tumors have an approved CAR-T and which are still trial-only.
What the Pivotal Trial Showed
The approval rests on CT041-ST-01, a multicentre, open-label, randomised phase 2 trial run in China, and the first randomised controlled study of a solid-tumor CAR-T anywhere. It enrolled 156 patients with Claudin18.2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma that had progressed after at least two prior lines, and randomised them 2:1 to satri-cel or to the investigator's choice of treatment.
| Endpoint, intention-to-treat | 恺力美 (satri-cel) | Physician's choice | Effect size |
|---|---|---|---|
| Median progression-free survival | 3.25 months | 1.77 months | HR 0.37 |
| Objective response rate | 22 percent | 4 percent | — |
| Median overall survival | 7.92 months | 5.49 months | HR 0.69 (95% CI 0.46–1.05) |
A hazard ratio of 0.37 for progression corresponds to roughly a 63 percent reduction in the risk of progression or death at any given moment, which is a large effect for a population this heavily pre-treated. The overall survival result is weaker evidence: the confidence interval crosses 1, so it is best described as a trend of clinically meaningful benefit rather than a demonstrated survival gain. It has to be read alongside the statistical boundary the trial was powered for, the amount of crossover and the length of follow-up.
All of it needs the context too. These are patients who had already failed at least two lines of therapy, for whom the remaining options were thin. In that setting, a prolongation of progression-free survival and a rise in response rate from 4 to 22 percent matter to a real person deciding how to spend the next six months. It is equally true that most patients did not respond, and that a solid-tumor CAR-T is not yet a universal solution.
Safety Is the Other Half of the Story
When CAR-T cells are activated and expand in large numbers they release inflammatory cytokines, which produces cytokine release syndrome. In CT041-ST-01 the incidence was 95 percent, the great majority grade 1 or 2, with about 4.5 percent grade 3. The study reported no cases of immune effector cell-associated neurotoxicity syndrome. Lymphodepletion and the cell therapy itself can also cause depletion of lymphocytes, white cells and neutrophils, and with that an increased infection risk.
Most of these events are manageable with protocolised monitoring and prompt intervention, but the qualifier carries the weight: manageable in an institution that holds a cell-therapy licence, runs a standardised manufacturing and cold-chain transport system, has dedicated beds and can mobilise multidisciplinary rescue. This is not a treatment that can be delivered safely by adding a protocol to a general oncology ward.
Zhongshan Hospital describes a full-pathway system built for exactly that: patient consultation, pre-assessment of records, multidisciplinary team decisions, target testing, apheresis, sample transport, bridging treatment, lymphodepletion, infusion, toxicity monitoring, management of complications, and long-term follow-up. The clinical value of a CAR-T programme sits as much in that operating discipline as in the molecule.
Who Can Be Assessed Today
Under the current label, a patient can be considered for evaluation only if all of the following hold: advanced gastric or gastro-oesophageal junction adenocarcinoma; tumour tissue tested positive for Claudin18.2; HER2-negative; at least two prior lines of systemic therapy given and failed; and a physical condition, organ function, infection status and recovery from previous treatment that can support apheresis, lymphodepletion and infusion.
Meeting those five points is not the same as being suitable. Tumour burden, the pace of progression, ascites or serous effusion, bone-marrow reserve, active infection, nutritional state, and whether bridging treatment is needed during the weeks of manufacturing all weigh on the decision. Those judgements belong to a multidisciplinary team, and the final word rests with the product label and the assessing centre.
Where the Field Goes Next
The first approval is a milestone, not an endpoint. The next generation of products is being upgraded along four lines at once.
From one target to several, and to logic gates
Dual-target and multi-target CAR-T designs aim to close the escape route used by antigen-negative cells. AND, OR and NOT logic-gate constructs go further, requiring a particular combination of markers before the cell activates at all, which raises tumour selectivity.
From killing cells to remodelling the surroundings
Armoured CAR-T cells are engineered to release cytokines, antibody fragments or other immune-modulating molecules locally. Checkpoint resistance and metabolic reprogramming strategies try to keep T cells functional in a hypoxic, immunosuppressive environment.
From intravenous infusion to better delivery
Local and regional administration, chemokine-receptor engineering and remodelling of the stromal barrier all aim to get more cells into the tumour faster and deeper.
From bespoke manufacturing to something faster
Off-the-shelf allogeneic products, in vivo CAR-T generated directly inside the patient, and automated manufacturing platforms could shorten the interval from apheresis to infusion and reduce manufacturing complexity. Safety, persistence and quality control remain unproven for all three.
Zhongshan Hospital has registered a phase 1 and 2 study of a hypoxia-inducible AXL and CD73 dual-target CAR-T for advanced gastric cancer. The design uses the hypoxic environment of a solid tumour as a molecular switch, so that the cells activate preferentially where oxygen is low. It is a deliberate attempt to buy selectivity and reduce off-tumour risk; whether it works, and whether it is safe, is exactly what the trial is for.
What This Means If You Are Considering Treatment in China
The practical position is narrower than the headlines suggest. One product is approved, for one disease, after two failed lines, in patients whose tumour tests positive for Claudin18.2 and negative for HER2. If the pathology does not fit, no amount of interest creates an approved option; the realistic question becomes whether a trial exists for that cancer type.
Testing is therefore the gate, and it should come before anything else. Claudin18.2 status is read from tumour tissue, typically by immunohistochemistry on a recent block or slide, and HER2 status needs to be current as well. Sending a pathology report and a recent scan for pre-assessment costs nothing and answers the eligibility question faster than any amount of reading.
Timing needs planning. Apheresis, manufacture, bridging treatment and infusion are not compressible into a short trip, and a patient who travels before the tumour is stable may end up receiving bridging therapy away from home. Most international patients should expect to be in China for several weeks, with follow-up arranged afterwards.
On cost: 恺力美 is priced at about 990,000 yuan at list. China's public medical insurance and the city-level supplementary schemes such as Huiminbao require Chinese residency and local enrolment, so international patients are normally quoted at list price plus hospital service fees rather than at any reimbursed rate.
See current list prices and the payment routes open to Chinese residents.
Three Questions Patients Ask Most
Is CAR-T a single injection and then it is over?
No. The infusion is one step in a long pathway. Before it come eligibility assessment, pathology review and target testing, then apheresis, individualised manufacture, possibly bridging treatment and lymphodepleting chemotherapy. Afterwards comes close monitoring for cytokine release syndrome, infection and cytopenias, then long-term follow-up.
If my tumour is Claudin18.2-positive, can I be treated?
A single test result is not enough to decide. HER2 status, how many lines of treatment you have had, how fast the disease is progressing, tumour burden, organ function and overall condition all enter the assessment, and the decision belongs to an experienced multidisciplinary team.
Can CAR-T cure advanced gastric cancer?
That is not a claim anyone can make today. A randomised phase 2 trial showed improved progression-free survival and a higher response rate, and some patients may achieve durable control, but individual outcomes vary widely and long-term efficacy still needs more follow-up and real-world data.
Key Reading
- CT041-ST-01, randomised phase 2 trial of satri-cel in gastric cancer (Lancet, 2025)
- Hypoxia-inducible AXL and CD73 dual-target CAR-T for advanced gastric cancer (NCT07333573)
- Engineering CAR-T cells for solid tumors: antigenic, trafficking and microenvironmental barriers (Frontiers in Immunology, 2026)
This is a report of published evidence, not a treatment recommendation.
It is based on the public account published by the Biological Therapy Centre of Zhongshan Hospital, Fudan University on 22 October 2026, on the CT041-ST-01 publication in The Lancet, and on the registered trial record for NCT07333573. Figures are quoted as reported; they describe trial populations and do not predict an individual outcome. Eligibility for any therapy described here depends on the individual case and on the protocol in force at the treating centre. This article is educational and is not medical advice.
Source: Biological Therapy Centre, Zhongshan Hospital, Fudan University (22 October 2026); Qi C, Liu C, Peng Z, et al. Lancet 2025;405(10494):2049–2060; ClinicalTrials.gov NCT07333573.